Serum human cartilage glycoprotein 39 as a marker of arthritis associated with inflammatory bowel disease

Annals of the Rheumatic Diseases

Volumn 62, Issue 12, 2003, Pages 1224-1226

  Punzi, L ^a   Podswiadek, M ^a   D'Inca R ^a   Zaninotto, M ^a   Bernardi, D ^a   Plebani, M ^a   Sturniolo, G C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 39;

ADULT; AGED; ARTHRITIS; ARTICLE; BLOOD LEVEL; CARTILAGE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADULT; AGED; ARTHRITIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED;

EID: 0345490894     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2002.004408     Document Type: Article

References (18)

1. Greenstein AJ, Janowitz HD, Sachar DB. The extraintestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55:401-12.
2. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel diseases: their articular distribution and natural history. Gut 1998;42:387-91.
3. Nielsen OH, Vainer B, Modsen MS, Seidelin JB, Heegard NHH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000;95:359-67.
4. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalion member of a chitinase protein family. J Biol Chem 1993;268:25803-10.
5. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 1979;77:843-6.
6. Powell-Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard-Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982 Jun;27:533-7.
7. Amor B, Dougados M, Listrat V, Menkes CJ, Dubost JJ, Roux H, et al. Evaluation of the Amor criteria for spondylarthropathies and European Spondylarthropathy Study Group (ESSG). A cross-sectional analysis of 2,228 patients. Ann Med Interne (Paris) 1991;142:85-9.
8. Smale S, Natt RS, Orchard TR, Russlel AS, Bjarnason I. Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum 2001;44:2728-36.
9. Kirkpatrik RB, Emery JG, Connor JR, Dodds R, Lysko PG, Rosenberg M. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp Cell Res 1997;237:46-54.
10. Volck B, Ostergaard K, Johansen JS, Garbbarsch C, Price PA. The distribution of YKL-40 in osteoarthritic and normal human articular cartilage. Scand J Rheumatol 1999;28:171-9.
11. Volck B, Johansen JS, Stoltenberg M, Garbarsch C, Price PA, Østergaard M, et al. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001;9:203-14.
12. Verheijden GFM, Rijnders AWM, Bos E, Coenen-de-Roo CJJ, van Staveren CJ, Miltenburg AMM, et al. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum 1997;40:1115-25.
13. Baeten D, Boots AM, Steenbakkers PG, Elewaut D, Bos E, Verhijden GF, et al. Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum 2000;43:1233-43.
14. Vos K, Steenbakkers P, Miltenburg AMM, Bos E, van den Heuvel MW, van Hogezand RA, et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and inflammatory conditions. Ann Rheum Dis 2000;59:544-8.
15. Johansen JS, Williamson MK, Rice JS, Price PA. The distribution of YKL-40 in osteoarthritic and normal human cartilage. Scand J Rheumatol 1999;28:171-9.
16. Johansen JS, Stoltenberg M, Hansen M, Florescu A, Horslev-Petersen K, Lorenzen I, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999;38:618-26.
17. Harvey S, Whaley J, Eberhardt K. The relationship between serum levels of YKL-40 and disease progression in patients with early rheumatoid arthritis. Scand J Rheumatol 2000;29:391-3.
18. Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29:959-65.